We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProBioGen Presents GlymaxX - The Novel Glyco-Engineering Technology
Product News

ProBioGen Presents GlymaxX - The Novel Glyco-Engineering Technology

ProBioGen Presents GlymaxX - The Novel Glyco-Engineering Technology
Product News

ProBioGen Presents GlymaxX - The Novel Glyco-Engineering Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ProBioGen Presents GlymaxX - The Novel Glyco-Engineering Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen announces the launch of its Glyco-Engineering Technology "GlymaxX" for the generation of afucosylated antibodies with strongly increased potency.

GlymaxX is a universally applicable technology to enhance the ADCC effector function and thus strongly boosting the cell-killing capability of therapeutic antibodies.

The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate. As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their productivity.

The applicability and efficiency of the GlymaxX technology have been confirmed already in feasibility studies of several major European pharmaceutical corporations. The GlymaxX technology is available to interested parties under a license.
Advertisement